ENTEROME ENTEROME
  • COMPANY
    • FOCUS
    • COLLABORATIONS
    • LEADERSHIP
  • TECHNOLOGY
    • PROGRAMS & PRODUCTS
  • PIPELINE
  • INVESTORS
  • NEWSROOM
    • PRESS RELEASES
    • CONFERENCES & EVENTS
  • CAREERS
  • CONTACT
ENTEROME ENTEROME
  • COMPANY
    • FOCUS
    • COLLABORATIONS
    • LEADERSHIP
  • TECHNOLOGY
    • PROGRAMS & PRODUCTS
  • PIPELINE
  • INVESTORS
  • NEWSROOM
    • PRESS RELEASES
    • CONFERENCES & EVENTS
  • CAREERS
  • CONTACT
Jun 01 2018

Enterome to Feature Promising Phase 1 clinical data with its Lead Candidate EB8018 for Crohn’s Disease at the Digestive Disease Week 2018

Paris, France and Cambridge, MA, USA – June 1, 2018 

ENTEROME SA, a clinical-stage biotech company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, announces it will, for the first time, present promising Phase 1 clinical data with its lead candidate EB8018 for Crohn’s disease at the Digestive Disease Week 2018 taking place in Washington, DC from June 2-5, 2018. 

The data, for which headline results were previously reported end of 2017, highlight EB8018’s good tolerability and safety in healthy volunteers across a range of doses tested. The compound also demonstrated a pharmacokinetic (PK) profile consistent with it being a gut-restricted molecule that is soluble in the gut and thereby able to act on its target in the gut microbiome. EB8018 also exhibited minimal absorption into the blood potentially limiting interactions with other drugs that are absorbed into the blood stream.

Enterome has initiated a Phase 1b clinical study with EB8018 in Crohn’s disease and the first patient is expected to be enrolled and dosed in the coming weeks.

The presentation details are below :

• Poster title: EB8018, a novel FimH blocker is well tolerated in a randomized, double-blind, placebo-controlled phase I study in healthy volunteers
• Abstract ID#: Sa1767
• Presenter: Jai Patel, Enterome CMO
• Poster presentation: Saturday 2 June, 12:00 – 14:00 EST, Session IBD: Controlled Clinical Trials in Humans, Hall C

The abstract is available online – click here.

top-header

Contact
Pierre Belichard, CEO
pbelichard@enterome.com

Media relations
Mark Swallow / Marine Perrier / David Dible
Citigate Dewe Rogerson
+44 207 638 9571
enterome@citigatedewerogerson.com

Investor relations
Lisa Pavelka
Rx Communications Group
Tel. +1 917 843 0223
lpavelka@rxir.com

top-header

About EB8018

EB8018 is a first-in-class, orally administered, gut restricted small molecule designed to selectively disarm virulent bacteria in the gut that cause inflammation without disrupting the gut microbiome. It blocks FimH receptors expressed on pro-inflammatory bacteria thereby preventing the interaction and attachment of these bacteria to specific receptors on the gut wall. These receptors have been implicated in the generation of inflammatory cytokines in patients with Crohn’s Disease.

About Enterome

Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD) and cancer.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.

Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel and gastro-intestinal diseases; and Bristol-Myers Squibb in immuno-oncology.

Enterome also has a 50/50 joint venture with Nestlé Health Science, called Microbiome Diagnostics Partners, focused initially on the development of novel microbiome-based diagnostics for IBD and liver diseases.

The Company was established in 2012 in Paris (France) to develop the discoveries made by the INRA metagenomic platform, and is backed by leading venture capital investors (Seventure Partners, Lundbeckfonden Ventures, Health for Life Capital, Omnes Capital and Principia) and strategic investors (BMS, Nestlé Health Science, Shire & INRA Transfert).

Additional information about Enterome is available through its website: www.enterome.com

top-header

Download the press release (.pdf format)

pr-en pr-fr

Comments are closed.

Categories

  • PRESS RELEASES
  • PRESS RELEASES 2020
  • PRESS RELEASES 2019
  • PRESS RELEASES 2018
  • PRESS RELEASES 2017
  • PRESS RELEASES 2016
  • PRESS RELEASES 2015
  • PRESS RELEASES 2014
  • CAREERS
  • PRESS
ETEROME-Bioscience

ENTEROME

94/96 avenue Ledru-Rollin
75011 PARIS, FRANCE
Tel : +33 (0)1 75 77 27 85
Email : info@enterome.com

INFORMATIONS

RCS Paris N° 508 580 289
Siret : 50858028900025
NAF : 7211Z
N° TVA : FR40 508 580 289

Legal notice • Privacy Policy • Cookie Policy
2021 ENTEROME — All rights reserved.
Lors de votre navigation sur notre site internet, nous sommes susceptibles de déposer des cookies sur votre appareil à des fins d’analyses et de performances. Vous avez la possibilité d’accepter, de refuser ou de paramétrer le dépôt de cookies.

When you navigate on our website, we may deposit cookies on your device for analysis and performance purposes. You are able to accept, refuse or configure the cookies' deposit. [ Read More ]

Cookie settings Reject Accept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Read more about our Privacy Policy.
Necessary
Always Enabled

The cookies defines under this category are absolutely essential for the website to function. Hence they are loaded by default irrespective if user consent.

CookieDescription
cookielawinfo-checkbox-necessaryThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-non-necessaryThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Non Necessary".
PHPSESSIDThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policyThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Analytics

Analytics cookies help us understand how our visitors interact with the website. It helps us understand the number of visitors, where the visitors are coming from, and the pages they navigate. The cookies collect this data and are reported anonymously.

CookieDescription
_gaThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gidThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

Performance

These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works.

CookieDescription
_gatThis cookies is installed by Google Universal Analytics to throttle the request rate to limit the colllection of data on high traffic sites.